Buch, Englisch, 1420 Seiten, Format (B × H): 210 mm x 267 mm, Gewicht: 3465 g
Two Volume Set
Buch, Englisch, 1420 Seiten, Format (B × H): 210 mm x 267 mm, Gewicht: 3465 g
ISBN: 978-93-7202-345-9
Verlag: JP Medical
Autoren/Hrsg.
Weitere Infos & Material
VOLUME 1
Preventive Cardiology (Section - 1)
1 Improving community level cardiac health awareness through school based education programs in India
2 Air Pollution & CVD in India: Current Perspective
3 Can we cancel out the excess Cardiovascular Risk Caused by Chronic Kidney Disease
4 Smoking Cessation: Never too Early, Never too Late
Hypertension (Section - 2)
5 Implications of Systolic Blood Pressure Time in Target Range
6 Artificial Intelligence - A Potential Tool in the Diagnosis and Management of Hypertension
7 Clinical Management of Primary Aldosteronism
8 Implications of Myocardial Interstitial Fibrosis in Hypertensive Heart Disease
9 Renovascular Hypertension: Kidney Intrinsic Mechanisms as Novel Targets
10 The Complexity of Resistant and Refractory Hypertension
Cardiometabolic (Section - 3)
11 Slowing cardiovascular aging by promoting cardiometabolic health
12 Obesity and Cardiovascular Disease
13 Myocardial Abnormalities Across the AHA - ACC Heart Failure Spectrum in Diabetic Patients Dyslipidemia Management (Section - 4)
14 Implications of lipid lowering therapy for premature CAD
15 The challenges in reducing Non-HDL- cholesterol.
16 Particle Number and Characteristics of Lipoprotein(a), LDL, and apoB: Contributions to ASCVD
17 Impact of Childhood Non-HDL Cholesterol and LDL Cholesterol on Adult Atherosclerotic Cardiovascular Events
Heart Failure (Section - 5)
18 WHF - How to Predict and Treat Early
19 Pulmonary hypertension in heart failure
20 Progression from Pre-Heart Failure, Heart Stress to Subclinical Heart Failure
21 Human immunology of heart failure
22 Identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure
23 Risk Scores in the Management of Heart Failure
24 Issues in Reversing Advanced Heart Failure
25 Early initiation of GDMT in HF
26 Mixed Cardiogenic-Vasodilatory Shock
27 Chronic right-sided heart failure and tricuspid regurgitation
28 Neuromodulation interventions in the management of heart failure
29 Congestion and Diuretic Resistance in WHF
30 Role of Imaging in Heart Failure Risk Stratification
31 Can Left Ventricular Wall Strain predict Heart Failure?
32 Medical therapy of cardiogenic shock
33 From Pre-shock to Classic Cardiogenic Shock
34 Triaging of Patients of ADHF
35 Gut hypothesis of heart failure: role of gut microbiota-derived metabolites
36 Strategies for Diuretic Intensification in Acute Heart Failure
37 Approaches in Heart Failure With Mildly Reduced and Preserved Ejection Fraction
38 Characteristics and Outcomes of Patients with Valvular Cardiogenic Shock
39 Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure
Cardiomyopathy (Section - 6)
40 Risk Predictors of Sudden Cardiac Death in Hypertrophic Cardiomyopathy
41 Monogenic to Polygenic Clinical Genetic Testing in Hypertrophic Cardiomyopathy
42 Dual Ischemic and Nonischemic Cardiomyopathy
43 Predicting Risk of Sudden Cardiac Death in Hypertrophic Cardiomyopathy by Myocardial Strain
44 Role of Clonal Haematopoiesis in the Pathogenesis of Dilated Cardiomyopathy
45 Dilated Cardiomyopathy in Systemic Immune-Mediated Diseases
46 Arrhythmia induced Cardiomyopathy
47 Alcoholic Cardiomyopathy
Congenital Heart Disease (Section - 7)
48 The Expanding Future of Sinus Venosus ASD Closure
49 Congenital Heart Disease Across the Lifespan: Clinical Risk Assessment and Prediction
50 Early Intervention for Tetralogy of Fallot
51 Novel Imaging Techniques for Congenital Heart Disease
52 Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease
53 Recent advances in the management of Adult Congenital Heart Disease-Related Heart Failure
54 Congenital Heart Disease in India: The Evolving Landscape
55 Echocardiography for Childhood Left Ventricular Noncompaction
56 Adults with congenital heart disease_ what every cardiologist should know about their care
57 Repaired Tetralogy of Fallot: Quest for a Lifelong Pulmonary Valve
Valvular Heart Disease (Section - 8)
58 Multiparametric Approach to Asymptomatic Aortic Stenosis
59 Secondary Mitral Regurgitation Phenotypes
60 Mitral Annular Disjunction in Mitral Valve Prolapse
61 An Update on High-Gradient “Moderate” Aortic Stenosis
62 Comprehensive Risk Phenotyping in Aortic Stenosis
63 When to Treat Young and Low-Risk Patients with Aortic Stenosis
64 Rheumatic Fever and Rheumatic Heart Disease Continuum: Recent Advances
65 Comprehensive Approach to Aortic Valve Pathophysiology by Fibro-Calcific Imaging
66 ESC 2025 Guidelines on Valvular Heart Disease
67 RHD in India: Current Perspective
Cardio-Obstetrics (Section - 9)
68 Cardiac Interventions in Pregnancy
69 Antepartum CV risk assessment and management of high-risk cardiac delivery.
70 Understanding and Managing Heart Failure during Pregnancy – What’s New in Peripartum Cardiomyopathy
71 Hypertensive Disorder of Pregnancy and Long-Term Cardiovascular Outcome
72 Understanding and Managing Anticoagulation during Pregnancy in Women with Heart Valves
Coronary Artery Disease (Section - 10)
73 Sarcopenia in Coronary Microvascular Dysfunction
74 Spontaneous Coronary Artery Dissection
75 Influence of Platelet biology and function on plaque erosion vs rupture
76 Coronary Artery Aneurysms
77 Atherosclerosis, Aortic Dissection, and Peripheral Artery Disease: New Therapeutic Targets
Cardiac Arrhythmia (Section - 11)
78 Stable VT in Ischemic Cardiomyopathy and LVEF < 35%: Ablation vs ICD
79 Long-term CV Outcome of Atrial Fibrillation
80 Effect of Left Atrial Dyssynchrony on Long-term Clinical Outcome during Cardiac Resynchronization Therapy
81 Real World Management of Cardiac Implantable Electronic Device Infections
82 Past, Present and Future of Leadless Pacing
83 Atrial fibrillation in Hf. Role of catheter ablation
84 Ablation of Ventricular Tachycardia in Emergency Situations
85 Prevention of Sudden Cardiac Death Beyond Automated External Defibrillators and Implantable Cardioverter Defibrillators
86 Current Perspective of Pulsed Field Ablation
87 Para-Hisian Ventricular Arrhythmias
Imaging (Section - 12)
88 Risk Stratification with CCTA derived Fractional Flow Reserve and Fractional Flow Reserve Gradient
89 Multi-modality Imaging in Multiple Valvular Heart Diseases
90 Role of LA Indices in the Management of Chronic Severe Aortic Regurgitation
91 Application of Emerging Hybrid Intracoronary Imaging Technologies in Clinical Practice and Research
92 Current Concepts and Clinical Implications of Coronary Artery Calcification
93 Cardiac CT: Emerging Role in Microvascular Dysfunction
94 Role of Cardiac Imaging for Optimizing Medical Therapy
VOLUME 2
STEMI (Section - 13)
95 P2Y12 Inhibitor Pretreatment in STEMI
96 STEMI Revascularization in India: Lessons Learnt from Punjab
97 Cardiac Magnetic Resonance Evaluation of LV Remodeling after Myocardial Infarction
98 Recurrent Thrombosis after Myocardial Infarction
99 STEMI Revascularization in India: Lessons Learnt from Tamil Nadu – 5 years experience
100 Thrombolysis in STEMI in Primary PTCA Era – Current Relevance in India
101 STEMI Revascularization in India: Lessons Learnt from Goa
102 Role of Novel Risk Factors in STEMI Among Young Women.
103 Transition from ST-Segment Elevation MI to Occlusion MI.
104 STEMI Revascularization in India: Role of Thrombolysis in Ambulance
105 Addressing delays in reperfusion therapy - Developing Chest Pain Clinics - A new initiative from STEMI India
106 Advanced Cardiac Patches in the Treatment of Myocardial Infarction
Coronary Intervention (Section - 14)
107 Thrombus Aspiration in Primary Angioplasty
108 Evaluation of Microvascular Dysfunction during Diagnostic Coronary Angiography
109 Prevention of progression of obesity and Cardiometabolic Disease: Intervention in School-Aged Children
110 Perforations in Complex PCI
111 Coronary Physiology by different Approaches for Guiding PCI
112 Left Main Bifurcation ISR - What to do?
113 Management of Drug - Eluting Stent In-Stent Restenosis
114 Bailout Strategies in CTO PCI
115 Metalless PCI
116 Percutaneous coronary intervention in high risk renal disorders:strategies for renal protection
117 Effect of Anatomical and Viability - Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy
118 Dual Antiplatelet Therapy in CKD: Duration and Bleeding Risk in Post PCI Patients
119 Technological Progress in Treating Calcified Lesion
120 PCI in Multivessel Coronary Artery Disease - Outcome According to the Coronary Lesion Complexity
Structural Intervention (Section - 15)
121 Transcatheter Aortic Valve Replacement in Heart Failure
122 Antithrombotic Selection Post - Left Atrial Appendage Occlusion
123 Predictors of Outcome of Re-interventions after TAVR
124 Implications of Left Bundle Branch Block in Aortic Stenosis beyond Pacemaker Implantation
125 Imaging of Transcatheter Valve Failure: An Update
126 Transcatheter Treatment of Pure Aortic Regurgitation
127 Transcatheter Mitral Therapy: Changing Context and Goals
128 Unveiling Right Ventricle Remodeling Following Tricuspid Valve Intervention
129 Resolving the Unmet Need for Treatment of Tricuspid Regurgitation
130 Bleeding after Transcatheter Structural Valve Interventions
HOT TOPICS (Section - 16)
PART 1: Heart Failure
131 Mitral Regurgitation in HF
132 Heart Failure and Aging
133 How does the Discontinuation of Long-Term Drug Treatment affectPatients With HFrEF
134 Metabolic defects in HFpEF and how to tackle them
135 Timing of Physical Activity and its impact on Cardiovascular Health
136 Impact of the EAT-Lancet Diet in Preventing Heart Failure
137 Cardiac Cachexia: Controversies and Conundrums
138 Therapeutic Inertia in the Treatment of HFrEF
139 ARNI-Induced Hypotension in HFrEF
140 The issue of Mortality Reduction in Patients With HFmrEF and HFpEF
141 HFrEF & HFpEF how they differ in advanced heart failure: A global perspective
142 Decongestion in acute heart failure: beyond diuretic-centred paradigm
143 Hepatic Biomarker Abnormalities in the Cardiac Intensive Care Unit Proposed Criteria for Cardiohepatic Syndrome
144 Bridging Atrial and Ventricular Failure Through Biomarkers
145 Ambulatory Advanced Heart Failure: Therapeutic Options
146 Interaction between Hypoalbuminemia and HF
147 Implications of Atrial Fibrillation for GDMT in Heart Failure
148 Challenges in Modifying Kidney Disease Progression in Patients With Heart Failure PART 2: Hypertension
149 Impact of Supranormal Left Ventricular Ejection Fraction, Concentric Remodeling in the Long-Term Survival
150 Brain Pathways in Regulating Blood Pressure
151 Update on Low-Renin Hypertension
152 Sodium, Interstitium, Lymphatics and Hypertension
153 Arterial Stiffness and Chronic Kidney Disease
PART 3: Coronary Artery Disease
154 Coronary Artery Spasm and Atherosclerotic Cardiovascular Disease
155 Peri-Infarct Ischemia and its Prognostic Significance
156 Hemorrhagic Myocardial Infarction
157 The issue of Stent Failure After PCI in patients with Diabetes Mellitus
158 Red blood cells as a new target for ASCVD prevention
159 Residual Chest Pain After PCI PART 4: Dislipidemia Management
160 HDL enhancing strategies and prevention of ASCVD
161 Cholesterol Screening and Management in Young Adults PART 5: Ischaemic Heart Disease
162 Vitamin D and Cardiovascular Risk
163 Testosterone and Cardiovascular Health
164 Primary Prevention for Intermediate CV Risk
165 Exposome in ischaemic heart disease
166 Interaction between Dietary Calcium and Vascular Calcification
167 Rethinking Beta Blocker in Stable Coronary Artery Disease
PART 6: Structural Intervention
168 PFO Closure for Stroke Prevention: An Illusion of Safety
PART 7: Heart & Brain
169 Role of Left Atrial Stiffness in the evaluation of Cryptogenic Stroke
PART 8: Cardiac Arrythmia
170 Appropriate use of defibrillator in non-ischaemic cardiomyopathy
171 Predicting Risk of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: role of Radiomics
172 Anticoagulation for atrial fibrillation in patients with intermediate stroke risk
173 Digging up Digoxin: Should We Stop Prescribing it? Current views and perspectives
PART 9: Amyloidosis
174 Prognostic role of Amyloid burden
175 Predictors of outcome in AL Amyloidosis Patients With Cardiac Involvement
Top 10 Papers (Section - 17)
176 Top 10 Papers in diabetes and metabolic disorders
177 Top 10 Papers in Anti-thrombotic
178 Top 10 papers in Lipids
179 Top 10 papers in Intervention
Viewpoint (Section - 18)
PART 1: Obesity Paradox is a Fact
180 An Unexpected Relationship Between Body Weight and Health Outcomes (Proponent)
181 Myth or Reality (Opponent)
PART 2: Time Matters when Considering Treatment for Patients with Mitral Regurgitation
182 Time Matters When Considering Treatment for Patients with Mitral Regurgitation (Proponent)
183 Time Matters When Considering Treatment for Patients with Mitral Regurgitation (Opponent)
184 CHAD-VASC of 1 Not Same for Every Patient with Afib
185 How to Resolve the Prosthesis - Patient Mismatch Debate
186 AI will Replace Clinical Cardiology
Miscellaneous (Section - 19)
187 Takayasu Arteritis - What is New?
188 Treatment of OSA & its impact on CVD
189 Participation in Sports by Athletes with CVD
190 Donor Selection for Heart Transplantation
191 Antithrombotic Therapies in Patients with Peripheral Artery Disease
192 Cardiology Training in India – Past Present and Future
193 Native Valve Infective Endocarditis: Recent Insights
194 Pulmonary Arterial Hypertension - no longer an orphan disease
195 Enigmas of the Athletic Heart
196 Cardiac Sarcoidosis: Diagnosis and Management
197 Marantic Endocarditis
198 Epilepsy and the heart: interaction between ‘brain arrhythmia’ and cardiac arrhythmia
